1039046-51-9Relevant articles and documents
Discovery of a potent, selective, and orally bioavailable c-met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl) -5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
Liu, Longbin,Siegmund, Aaron,Xi, Ning,Kaplan-Lefko, Paula,Rex, Karen,Chen, April,Lin, Jasmine,Moriguchi, Jodi,Berry, Loren,Huang, Liyue,Teffera, Yohannes,Yang, Yajing,Zhang, Yihong,Bellon, Steven F.,Lee, Matthew,Shimanovich, Roman,Bak, Annette,Dominguez, Celia,Norman, Mark H.,Harmange, Jean-Christophe,Dussault, Isabelle,Kim, Tae-Seong
, p. 3688 - 3691 (2008)
Deregulation of the receptor tyrosine kinase c-Met has been implicated in human cancers. Pyrazolones with N-1 bearing a pendent hydroxyalkyl side chain showed selective inhibition of c-Met over VEGFR2. However, studies revealed the generation of active, n
N - acyl aniline c - Met kinase inhibitor preparation method and use thereof
-
Paragraph 0067; 0078-0080, (2019/07/04)
The invention relates to the field of pharmaceutical chemistry, and in particular relates to N - acyl aniline derivatives, process for their preparation, pharmaceutical compositions containing these compounds and their use for medical purposes, in particu
